Age as a prognostic factor in small cell lung cancer:a pooled analysis of randomized clinical trials from the Manchester lung cancer group (MLCG) and theUK medical research council clinical trials unit (MRC CTU)
Paul Wheatley‐Price(University of Ottawa), Fiona Blackhall(University of Manchester), Linda Ashcroft(The Christie NHS Foundation Trust), Shane White, Nicholas Thatcher(The Christie NHS Foundation Trust), Paul Lorigan(Manchester Academic Health Science Centre), Elham Sabri(Ottawa Hospital)
Research Explorer (The University of Manchester)
November 1, 2013
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k